AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase III clinical study titled A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure. The study aims to evaluate the effectiveness, safety, and tolerability of combining Baxdrostat with Dapagliflozin compared to Dapagliflozin alone, focusing on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (CKD) and hypertension.
The intervention being tested involves two treatments: an experimental combination of Baxdrostat and Dapagliflozin, and a placebo with Dapagliflozin. Baxdrostat is intended to enhance renal and cardiovascular outcomes when used with Dapagliflozin, a standard treatment for CKD and high blood pressure.
This study is designed as a randomized, double-blind, placebo-controlled trial with a parallel-group model. It involves quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose of this study is treatment-focused.
The study began on March 3, 2025, with the last update submitted on July 1, 2025. These dates are crucial as they mark the commencement of participant recruitment and the latest information available about the study’s progress.
The outcome of this study could significantly impact AstraZeneca’s stock performance and investor sentiment, as positive results may enhance the company’s position in the competitive market for CKD and hypertension treatments. Competitors in the pharmaceutical industry will be closely monitoring these developments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.